Results 251 to 260 of about 434,903 (321)
Chemical Approaches for Functionally Probing the Proteome [PDF]
Doron C. Greenbaum+6 more
openalex +1 more source
Among-population proteomic differences in Schistocephalus solidus based on excretory/secretory and total body protein predictions. [PDF]
Wang A, Bolnick DI.
europepmc +1 more source
Thiol reductants activate dichalcogenide probes by a cascade of partly reversible steps. Careful dichalcogenide engineering can tune the rates of these steps separately, to aim at probes that are kinetically selective for specific oxidoreductases in live cells.
Lukas Zeisel+6 more
wiley +2 more sources
In-Depth Cell-Type-Specific Proteome Landscape of the Brain from Human Amyloid-β Overexpression Mouse Model. [PDF]
Ryu T+6 more
europepmc +1 more source
Kidney stones cause significant pain and healthcare costs. Current prediction, diagnosis, and treatment options are limited. Extracellular vesicles (EVs), rich in proteins, lipids, and nucleic acids, offer a promising solution. This review explores the roles of EVs in kidney stone management, highlighting their potential as biomarkers and therapeutic ...
Wang Zhu+3 more
wiley +1 more source
To monitor small molecule‐induced changes in protein polyubiquitination in an unbiased manner, we employ enrichment through tandem ubiquitin binding entities coupled to LC‐MS/MS analysis (TUBE‐MS). By applying the workflow to PROTAC, p97‐ and deubiquitinase‐inhibitor treatment of cells, we demonstrate its broad applicability and reveal the induction of
Siska Führer+6 more
wiley +2 more sources
Editorial: Exploring small molecule probes: advancements and applications in pharmacological research. [PDF]
Yeh IJ.
europepmc +1 more source
Biomimetic microdevices are redefining anticancer drug screening by mimicking complex tumor microenvironments. This review highlights advances in microfluidic systems, cell microarrays, and in vivo‐like models, offering new insights into drug efficacy prediction and personalized medicine. The development of effective anticancer drugs remains a critical
Ching‐Te Kuo+2 more
wiley +1 more source
When cellular iron is low, bacterioferritin (Bfr) releases its stored iron through a reductive process dependent on the [2Fe–2S] ferredoxin Bfd. Why accessing stored iron should depend on an iron‐requiring protein when iron is scarce is unclear. Here, we show that the Bfd [2Fe–2S] cluster is sensitive to oxidative stress, suggesting that it may act as ...
Justin M. Bradley+4 more
wiley +2 more sources